Adam E I, Gore S M, Price W H
J R Coll Gen Pract. 1978 Oct;28(195):587-90.
The value of clonidine (;Dixarit') for the prophylaxis of migraine has been assessed by a double blind cross-over trial. A dose of up to 0.15 mg daily was used. No effect on the frequency of the headaches could be detected over and above the 60 per cent reduction observed with a placebo. Severity, assessed subjectively by the patient, when it varied between placebo and clonidine, was less with clonidine (p<0.01). There was also some evidence that headaches lasting more than 12 hours were less common during treatment with the drug.
通过双盲交叉试验评估了可乐定(;Dixarit')预防偏头痛的价值。每日使用剂量高达0.15毫克。除了使用安慰剂观察到的60%的减少率之外,未发现对头痛频率有任何影响。当患者主观评估的严重程度在安慰剂和可乐定之间有所不同时,可乐定的严重程度较低(p<0.01)。也有一些证据表明,在使用该药物治疗期间,持续超过12小时的头痛较少见。